[go: up one dir, main page]

UY29285A1 - Macrolidos - Google Patents

Macrolidos

Info

Publication number
UY29285A1
UY29285A1 UY29285A UY29285A UY29285A1 UY 29285 A1 UY29285 A1 UY 29285A1 UY 29285 A UY29285 A UY 29285A UY 29285 A UY29285 A UY 29285A UY 29285 A1 UY29285 A1 UY 29285A1
Authority
UY
Uruguay
Prior art keywords
compounds
methods
macrolidos
famraceutical
intermediates
Prior art date
Application number
UY29285A
Other languages
English (en)
Inventor
Takushi Kaneko
Mark Edward Flanagan
Louis Stanley Chupak
Thomas Victor Magee
Mark Carl Noe
Usa Reilly
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35809765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY29285(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY29285A1 publication Critical patent/UY29285A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Tires In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Compuestos macrólidos per se, como se muestran a continuación y se definen en esta memoria, y su uso, p. ej., como agentes antibacterianos y antiprotozoarios en animales, incluyendo seres humanos: También se describen métodos para preparar los compuestos, productos intermedios y sus composiciones famracéuticas, y métodos para tratar o prevenir la enfermedad por administración de los compuestos a los sujetos que lo necesiten, Este resumen es sólo un extracto y no limita la invención.
UY29285A 2004-12-21 2005-12-21 Macrolidos UY29285A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63809704P 2004-12-21 2004-12-21
US71753005P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
UY29285A1 true UY29285A1 (es) 2006-07-31

Family

ID=35809765

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29285A UY29285A1 (es) 2004-12-21 2005-12-21 Macrolidos

Country Status (35)

Country Link
US (1) US7462600B2 (es)
EP (2) EP2233493A1 (es)
JP (1) JP4111994B1 (es)
KR (1) KR100897678B1 (es)
CN (1) CN101120011A (es)
AP (1) AP2007004026A0 (es)
AR (1) AR052824A1 (es)
AT (1) ATE459633T1 (es)
AU (1) AU2005317735B2 (es)
BR (1) BRPI0519135A2 (es)
CA (1) CA2591746A1 (es)
CR (1) CR9202A (es)
DE (1) DE602005019786D1 (es)
DK (1) DK1836211T3 (es)
EA (1) EA011281B1 (es)
ES (1) ES2339871T3 (es)
GE (1) GEP20094834B (es)
GT (1) GT200500378A (es)
HN (1) HN2005036113A (es)
HR (1) HRP20100253T1 (es)
IL (1) IL183661A0 (es)
MA (1) MA29108B1 (es)
MX (1) MX2007007598A (es)
NL (1) NL1030713C2 (es)
NO (1) NO20073367L (es)
PE (1) PE20060948A1 (es)
PL (1) PL1836211T3 (es)
PT (1) PT1836211E (es)
SI (1) SI1836211T1 (es)
TN (1) TNSN07233A1 (es)
TW (1) TW200626608A (es)
UA (1) UA85937C2 (es)
UY (1) UY29285A1 (es)
WO (1) WO2006067589A1 (es)
ZA (1) ZA200705108B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
HRP20171285T1 (hr) 2005-08-24 2017-10-20 Melinta Therapeutics, Inc. Spojevi triazola i postupci dobivanja i njihova upotreba
WO2008110918A2 (en) * 2007-03-13 2008-09-18 Pfizer Products Inc. Erythromycin-based macrolides
AU2008227216A1 (en) * 2007-03-21 2008-09-25 Creative Antibiotics Sweden Ab Method and means for preventing and inhibiting type III secretion in infections caused by gram-negative bacteria
WO2009053259A1 (en) * 2007-10-25 2009-04-30 Sandoz Ag Process for the production of telithromycin
AU2008316830B2 (en) 2007-10-25 2016-03-17 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2225239B1 (en) 2007-12-21 2014-10-22 F. Hoffmann-La Roche AG Heterocyclic antiviral compounds
WO2011018510A1 (en) * 2009-08-13 2011-02-17 Basilea Pharmaceutica Ag New macrolides and their use
NZ602544A (en) * 2010-03-22 2014-11-28 Cempra Pharmaceuticals Inc Crystalline forms of a macrolide, and uses therefor
WO2012142125A2 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
CN102558047B (zh) * 2011-12-14 2013-10-30 天津药物研究院药业有限责任公司 3-甲基喹啉的制备方法
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
RU2015103119A (ru) 2012-07-13 2016-08-27 Ф. Хоффманн-Ля Рош Аг Антипролиферативные бензо[в]азепин-2-оны
KR101612179B1 (ko) * 2013-04-19 2016-04-12 영남대학교 산학협력단 아미도피리딘올 유도체 또는 이의 약제학적 허용가능한 염을 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
CN103739643A (zh) * 2013-12-30 2014-04-23 华东理工大学 利用分子印迹技术对红霉素进行回收分离纯化的方法
CN104230891B (zh) * 2014-08-27 2016-03-30 于宗光 一种托匹司他的制备方法
EP3522896A4 (en) 2016-10-04 2020-06-17 Biopharmati SA KETOLID WITH ANTIBACTERIAL EFFECT
CN114340616A (zh) * 2019-06-04 2022-04-12 海格生物科学有限责任公司 作为食欲肽拮抗剂的吡唑和咪唑衍生物、组合物以及方法
SG11202112827QA (en) 2019-06-04 2021-12-30 Hager Biosciences Llc Imidazolo derivatives, compositions and methods as orexin antagonists
CN111793022A (zh) * 2020-04-27 2020-10-20 滁州拜奥生物科技有限公司 一种3-甲基喹啉的制备方法
CN120417896A (zh) * 2022-09-01 2025-08-01 海格生物科学有限责任公司 作为食欲素和κ-阿片受体双重调节剂的吡唑和咪唑衍生物、组合物、用于治疗神经和精神病患的方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653899A (en) 1952-04-14 1953-09-29 Lilly Co Eli Erythromycin, its salts, and method of preparation
US2823203A (en) 1954-06-24 1958-02-11 Abbott Lab Method of producing substantially pure erythromycin a
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
YU43006B (en) 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
US5075289A (en) 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5523399A (en) 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5629322A (en) 1994-11-15 1997-05-13 Merck & Co., Inc. Cyclic amidine analogs as inhibitors of nitric oxide synthase
FR2727969B1 (fr) 1994-12-09 1997-01-17 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5747466A (en) 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
US5750510A (en) 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
JP2000509712A (ja) 1996-05-07 2000-08-02 アボツト・ラボラトリーズ ６―ｏ―置換エリスロマイシン及びその製造方法
FR2748746B1 (fr) 1996-05-14 1998-08-14 Hoechst Marion Roussel Inc Nouveau procede d'isomerisation du radical methyle en 10 de derives de l'erythromycine
US6271255B1 (en) 1996-07-05 2001-08-07 Biotica Technology Limited Erythromycins and process for their preparation
FR2751656B1 (fr) 1996-07-24 1998-10-16 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
CN1273475C (zh) 1996-09-04 2006-09-06 艾博特公司 具有抗细菌活性的6－0－取代的酮基内酯类化合物
US5804565A (en) 1996-09-24 1998-09-08 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
CN1238777A (zh) 1996-11-27 1999-12-15 大正制药株式会社 红霉素a衍生物
US6140479A (en) 1997-03-24 2000-10-31 Taisho Pharmaceuticals Co., Ltd. Erythromycin a derivatives
US6162794A (en) 1997-05-09 2000-12-19 Pfizer Inc. Erythromycin derivatives
US20020025937A1 (en) 2000-03-20 2002-02-28 Yong-Jin Wu 9-oxime erythromycin derivatives
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
ZA987689B (en) 1997-09-02 1999-02-24 Abbott Lab 3-descladinose 6-O substituted erythromycin derivatives
US6034069A (en) 1997-09-30 2000-03-07 Abbott Laboratories 3-'N-modified 6-O-substituted erythromycin ketolide derivatives having antibacterial activity
PA8461401A1 (es) 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
ZA989835B (en) 1997-10-29 1999-05-05 Taisho Pharmaceutical Co Ltd Erythromycin a derivatives
AP1060A (en) 1998-01-02 2002-04-23 Pfizer Prod Inc Novel erythromycin derivatives.
AP9801420A0 (en) 1998-01-02 1998-12-31 Pfizer Prod Inc Novel macrolides.
EP0941998B1 (en) 1998-03-03 2004-09-01 Pfizer Products Inc. 3,6-ketal macrolide antibiotics
US5955440A (en) 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
AU3439899A (en) 1998-06-03 1999-12-20 Pfizer Products Inc. Tricyclic 3-keto derivatives of 6-o-methylerythromycin
JP4573925B2 (ja) 1998-07-09 2010-11-04 アベンティス・ファーマ・ソシエテ・アノニム 新規のエリスロマイシン誘導体、その製造方法及びその薬剤としての使用
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
US6262030B1 (en) 1998-11-03 2001-07-17 Pfizer Inc. Erythromycin derivatives
TR200200436T2 (tr) 1998-11-03 2002-06-21 Pfizer Inc. Yeni makrolit antibiyotikler
WO2000034297A1 (en) 1998-12-10 2000-06-15 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
SI1147121T1 (en) 1999-01-27 2004-04-30 Pfizer Products Inc. Ketolide antibiotics
US6054435A (en) 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6939861B2 (en) 1999-04-16 2005-09-06 Kosan Biosciences, Inc. Amido macrolides
CN1373767A (zh) * 1999-04-16 2002-10-09 奥索-麦克尼尔药品公司 酮式大环内酯抗菌剂
KR20020007374A (ko) 1999-04-16 2002-01-26 추후제출 매크롤라이드 항감염제
US20020077302A1 (en) 1999-04-23 2002-06-20 Yong-Jin Wu Tricyclic erythromycin derivatives
US20020061857A1 (en) 1999-04-23 2002-05-23 Yong-Jin Wu 9-amino-3-oxo erythromycin derivatives
US6355620B1 (en) 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
SK15162001A3 (sk) 1999-05-24 2003-02-04 Pfizer Products Inc. Deriváty 13-metylerytromycínu
JP2001072669A (ja) 1999-09-07 2001-03-21 Showa Kako Kk ７−クロロ−２，４（１ｈ，３ｈ）−キナゾリンジオンの製造方法
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
EP1114826A3 (en) 1999-12-29 2001-10-31 Pfizer Products Inc. Novel antibacterial and prokinetic macrolides
EP1122261A3 (en) 2000-01-31 2001-09-26 Pfizer Products Inc. 13 and 14-membered antibacterial macrolides
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
EP1146051A3 (en) 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US20020061856A1 (en) 2000-04-24 2002-05-23 Yong-Jin Wu Novel tricyclic erythromycin derivatives
TR200401847T4 (tr) 2000-06-30 2004-09-21 Pfizer Products Inc. Makrolit antibiyotikler.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
HUP0302526A2 (hu) 2000-12-21 2003-11-28 Glaxo Group Limited Makrolid vegyületek, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
US20020132782A1 (en) 2001-01-18 2002-09-19 Zhenkun Ma 9-amino erythromycin derivatives with antibacterial activity
CA2451391A1 (en) 2001-07-03 2003-01-16 Chiron Corporation C12 modified erythromycin macrolides and ketolides having antibacterial activity
WO2005070918A1 (en) 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US7064110B2 (en) 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
MXPA05011276A (es) 2003-04-21 2006-01-24 Daiichi Seiyaku Co Derivado heterociclico de cinco miembros.
RU2397987C2 (ru) 2004-07-28 2010-08-27 Рэнбакси Лабораториз Лимитед Кетолидные производные в качестве антибактериальных агентов
EP1807439A2 (en) 2004-10-25 2007-07-18 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
GB0424951D0 (en) 2004-11-11 2004-12-15 Glaxo Group Ltd Novel compounds
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
US7291602B2 (en) 2004-12-13 2007-11-06 Enanta Pharmaceuticals, Inc. 11,12-lactone bicyclolides
TW200635600A (en) 2004-12-13 2006-10-16 Enanta Pharm Inc Tetracyclic bicyclolides

Also Published As

Publication number Publication date
JP2008524319A (ja) 2008-07-10
HN2005036113A (es) 2010-12-06
PT1836211E (pt) 2010-04-08
EP2233493A1 (en) 2010-09-29
EA011281B1 (ru) 2009-02-27
TNSN07233A1 (fr) 2008-11-21
EA200701113A1 (ru) 2007-12-28
HRP20100253T1 (hr) 2010-06-30
ZA200705108B (en) 2009-01-28
MX2007007598A (es) 2007-07-25
JP4111994B1 (ja) 2008-07-02
GEP20094834B (en) 2009-11-25
CR9202A (es) 2007-07-16
NL1030713A1 (nl) 2006-06-22
ATE459633T1 (de) 2010-03-15
SI1836211T1 (sl) 2010-04-30
IL183661A0 (en) 2007-09-20
US7462600B2 (en) 2008-12-09
KR100897678B1 (ko) 2009-05-14
AU2005317735B2 (en) 2009-06-04
MA29108B1 (fr) 2007-12-03
UA85937C2 (uk) 2009-03-10
AP2007004026A0 (en) 2007-06-30
KR20070089191A (ko) 2007-08-30
CN101120011A (zh) 2008-02-06
EP1836211A1 (en) 2007-09-26
WO2006067589A1 (en) 2006-06-29
AU2005317735A1 (en) 2006-06-29
US20060135447A1 (en) 2006-06-22
NL1030713C2 (nl) 2006-12-12
ES2339871T3 (es) 2010-05-26
BRPI0519135A2 (pt) 2008-12-23
NO20073367L (no) 2007-09-05
EP1836211B1 (en) 2010-03-03
DK1836211T3 (da) 2010-05-17
PE20060948A1 (es) 2006-10-11
GT200500378A (es) 2006-11-28
PL1836211T3 (pl) 2010-07-30
TW200626608A (en) 2006-08-01
DE602005019786D1 (de) 2010-04-15
AR052824A1 (es) 2007-04-04
CA2591746A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
CR9202A (es) Macrolidos
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
HN2011001593A (es) Piridiloxi-indoles del vegf-r2 y uso de los mismos para el tratmiento de enfermedades
CR9781A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY31539A1 (es) Agentes antelminticos y su uso
PA8570901A1 (es) Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso
PA8595901A1 (es) "n-arilheterociclos sustituidos, procedimientos para su preparacion, y su empleo como medicamentos
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY29283A1 (es) Anticuerpos ab(beta)usados en mejorar la cognicion
HN2000000041A (es) Compuestos para tratar la obesidad
CR20120264A (es) Compuestos
CU23779B7 (es) Compuestos de pirazolina y su uso y composiciones farmacéuticas
DK2219665T3 (da) Parathyroidhormonformuleringer og anvendelse deraf
PA8803201A1 (es) Derivados acidos de cicloalquilamino
AR035284A1 (es) Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion
PA8599401A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
CL2004000710A1 (es) Composicion antimicrobiana y antiparasitaria formada por un antibiotico derivado del cloranfenicol o tianfenicol, un endectocida y por lo menos un vehiculo aceptable, y su uso para tratar enfermedades respiratorias y parasitarias de los bovinos.
PA8797801A1 (es) Uso de n-fenilamidas de acido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UY29417A1 (es) Agentes endoparasiticidas
DOP2005000267A (es) Macrolidos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160606